Company profile
MEDIWOUND LTD.
NASDAQ:MDWDMedicinal Chemicals and Botanical Products
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| STEM BROMELAIN | phase3 | — | 5 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06568627 | phase3 | recruiting | 2025-06-01 | 2026-12-01 | MediWound Ltd | A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE) |
| NCT04817228 | phase2 | completed | 2021-04-21 | 2022-05-06 | MediWound Ltd | A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg Ulcers |
| NCT02278718 | phase3 | completed | 2015-05-01 | 2021-04-01 | MediWound Ltd | A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care |
| NCT02148705 | phase3 | completed | 2015-05-27 | 2018-06-12 | MediWound Ltd | A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns |
| NCT05157763 | phase1_2 | recruiting | 2021-06-30 | 2022-05-01 | MediWound Ltd | A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma |
FDA applications (0)
No records yet.